Evidence map›Paper›PMID 36726139›Full record

ArticleBMC veterinary research2023

Effects of a water-soluble formulation of tylvalosin on disease caused by porcine reproductive and respiratory syndrome virus alone in sows or in combination with Mycoplasma hyopneumoniae in piglets.

Alfonso Lopez Rodriguez, Veronica L Fowler, Michael Huether, David Reddick, Christine Tait-Burkard, Marie O'Shea, Stephanie Perkins, Nirosh Dias, Robin Buterbaugh, Hafid A Benchaoui

Open access · goldAbstract read
In one paragraph

Article in BMC veterinary research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Use of Subtherapeutic Tylvalosin AgainstTransboundary and emerging diseases · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Alfonso Lopez RodriguezECO Animal Health Ltd, London, UK. alfonso.lopez@ecoanimalhealth.com.
Veronica L FowlerECO Animal Health Ltd, London, UK.
Michael HuetherECO Animal Health Ltd, London, UK.
David ReddickMoredun Scientific Ltd, Pentlands Science Park, Bush Loan, Penicuik, Midlothian, EH26 0PZ, UK.
Christine Tait-BurkardThe Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, Midlothian, EH25 9RG, UK.
Marie O'SheaThe Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, Midlothian, EH25 9RG, UK.
Stephanie PerkinsRTI, LLC, 801 32nd Ave, Brookings, SD, 57006, USA.
Nirosh DiasRTI, LLC, 801 32nd Ave, Brookings, SD, 57006, USA.
Robin ButerbaughRTI, LLC, 801 32nd Ave, Brookings, SD, 57006, USA.
Hafid A BenchaouiECO Animal Health Ltd, London, UK.
Moredun Research Institute · GBRoslin Institute · GBUniversity of Edinburgh · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe effect of a water-soluble formulation of tylvalosin (Aivlosin® 625 mg/g granules) on disease caused by porcine reproductive and respiratory syndrome virus (PRRSV) and Mycoplasma hyopneumoniae (Mhyop) was investigated in two animal studies. In a PRRSV challenge model in pregnant sows (n = 18), six sows received water medicated at target dose of 5 mg tylvalosin/kg body weight/day from 3 days prior to challenge until the end of gestation. Six sows were left untreated, with a third group remaining untreated and unchallenged. Sows were challenged with PRRSV-2 at approximately 85 days of gestation. Cytokines, viremia, viral shedding, sow reproductive parameters and piglet performance to weaning were evaluated. In a dual infection study (n = 16), piglets were challenged with Mhyop on days 0, 1 and 2, and with PRRSV-1 on day 14 and euthanized on day 24. From day 10 to 20, eight piglets received water medicated at target dose of 20 mg tylvalosin/kg body weight/day and eight piglets were left untreated. Cytokines, viremia, bacteriology and lung lesions were evaluated.

resultsIn the PRRSV challenge study in pregnant sows, tylvalosin significantly reduced the levels of serum IL-8 (P < 0.001), IL-12 (P = 0.032), TNFα (P < 0.001) and GM-CSF (P = 0.001). IL-8 (P = 0.100) tended to be lower in uterus of tylvalosin sows. All piglets from tylvalosin sows surviving to weaning were PRRSV negative in faecal swabs at weaning compared to 33.3% PRRSV positive piglets from untreated sows (P = 0.08). In the dual challenge study in piglet, tylvalosin reduced serum IL1β, IL-4, IL-6, IL-8, IL-10, IL-12, IL-1α, IL-13, IL-17A, IL-18, GM-CSF, TGFβ1, TNFα, CCL3L1, MIG, PEPCAM-1 (P < 0.001) and increased serum IFNα, IL-1ra and MIP-1b (P < 0.001). In the lungs, tylvalosin reduced IL-8, IL-10 and IL-12 compared to untreated pigs (P < 0.001) and tended to reduce TNFα (P = 0.082). Lung lavage samples from all tylvalosin treated piglets were negative for Mhyop (0 cfu/mL) compared to the untreated piglets which had mean Mhyop counts of 2.68 × 10

conclusionOverall, tylvalosin reduced both local and systemic proinflammatory cytokines after challenge with respiratory pathogens in sows and in piglets. Tylvalosin was effective in reducing Mhyop recovery from the lungs and may reduce virus shedding in piglets following transplacental PRRSV infection in sows.

Indexed as

Mycoplasma hyopneumoniaePorcine Reproductive and Respiratory SyndromePorcine respiratory and reproductive syndrome virusSwine DiseasesAnimalsBody WeightCytokinesFemaleGranulocyte-Macrophage Colony-Stimulating FactorInterleukin-10Interleukin-12Interleukin-8PregnancySwineTumor Necrosis Factor-alphaTylosinCytokinesGranulocyte-Macrophage Colony-Stimulating FactorInterleukin-10Interleukin-12Interleukin-8Tumor Necrosis Factor-alphaTylosintylvalosinImmunomodulationMacrolideMycoplasma hyopneumoniaePorcine reproductive and respiratory virusPro-inflammatory cytokinesPRRSTylvalosin

Identifiers

PMID36726139
PMCPMC9890818
OpenAlexW4318917674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.